SCHEMBL2801637

SCHEMBL2801637

CCS(=O)(=O)NC(=O)c1cnn2c(Nc3cccc(Cl)c3C)c(C(=O)N3CCC(c4ccccc4)CC3)cnc12

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIRT5 Q9NXA8 3/20 0.41
EGLN1 Q9GZT9 1/20 0.40
TP53 P04637 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
SIRT2 Q8IXJ6 1/20 0.37
CCKBR P32239 1/20 0.37
SPR P35270 2/20 0.37
ALDH1A1 P00352 1/20 0.36
FASN P49327 1/20 0.36
LMNA P02545 1/20 0.36
F11 P03951 1/20 0.36
USP5 P45974 1/20 0.36
SCN9A Q15858 1/20 0.36
MGLL Q99685 1/20 0.36
HCRTR2 O43614 1/20 0.35
NPC1 O15118 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2800478 0.95 SIRT5 (0.46) SIRT5EGLN1SMN1; SMN2SIRT2CCKBR
SCHEMBL2802799 0.92 ALDH1A1 (0.40) SIRT5EGLN1TP53SMN1; SMN2SPR
SCHEMBL2803213 0.91 NPC1 (0.40) SIRT5TP53SPRALDH1A1FASN
SCHEMBL2799996 0.90 SIRT5 (0.40) SIRT5EGLN1TP53SMN1; SMN2SIRT2
SCHEMBL2801762 0.90 EGLN1 (0.39) SIRT5EGLN1TP53CCKBRSPR
SCHEMBL2803776 0.89 SPR (0.38) SIRT5SMN1; SMN2SPRALDH1A1FASN
SCHEMBL2801510 0.89 EGLN1 (0.38) SIRT5EGLN1SPRALDH1A1FASN
SCHEMBL2801684 0.89 LMNA (0.45) SIRT5EGLN1TP53SMN1; SMN2SIRT2
SCHEMBL2799384 0.89 NPC1 (0.38) SIRT5EGLN1SPRALDH1A1FASN
SCHEMBL2801754 0.88 ALDH1A1 (0.42) SIRT5EGLN1SMN1; SMN2SIRT2CCKBR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2206714-B1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO LTD (JP) 2015-01-21 EP disclosed
US-8729264-B2 Agent for prevention and/or treatment of skin diseases KYOWA HAKKO KIRIN CO., LTD. (JP) 2014-05-20 US disclosed
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES KYOWA HAKKO KIRIN CO., LTD. (JP) 2010-10-07 US disclosed
EP-2206714-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES Kyowa Hakko Kirin Co., Ltd. (JP) 2010-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256134-A1 AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES TYR, CUTA, SERPINB1 SIRT5 2237/4885EGLN1 1967/4885TP53 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.